SCHEDULE: ADAR1 Capital Discloses 9.9% Stake in Equillium, Inc.

ADAR1 Capital Management and Daniel Schneeberger have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Equillium, Inc.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger reported a combined beneficial ownership of 6,603,754 shares of Equillium, Inc. common stock.
• The reported stake represents 9.9% of the issuer's outstanding common stock as of March 31, 2026.
• The holdings include 2,786,136 shares held by ADAR1 Partners, LP, 404,699 shares held by Spearhead Insurance Solutions IDF, LLC, 533,742 shares held by ADAR1 SPV I, LP, 2,082 shares in managed accounts, and 2,877,095 shares underlying prefunded warrants.
• The filing confirms the acquisition was made in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure of institutional shareholding that does not signal a change in company strategy or management.

Positives

• Significant institutional interest indicated by a 9.9% ownership stake.
• The reporting persons have certified that the shares were acquired in the ordinary course of business, suggesting a passive investment strategy.

Negatives

• The ownership stake is close to the 10% threshold, which often triggers additional regulatory scrutiny and reporting requirements.

Risks

• Beneficial ownership is subject to a 9.99% limitation on the exchange and exercise of certain prefunded warrants.
• The investment is subject to market volatility inherent in the biotechnology sector where Equillium operates.

Future Outlook

The reporting persons have stated they do not intend to change or influence the control of the issuer, indicating a passive investment outlook.

Management Comments

• The reporting persons certify that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects typical institutional accumulation patterns in the small-cap biotech sector, where investment firms often take significant positions in companies with upcoming clinical milestones or potential value inflection points.

Comparison to Industry Standards

• The 9.9% stake is a standard threshold for institutional investors to maintain passive status while maximizing influence without triggering 'insider' or 'control person' regulatory burdens.
• The use of prefunded warrants is a common financing structure in the biotech industry to manage dilution and regulatory ownership caps.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a vote of confidence in the company's long-term prospects.

Next Steps

• The reporting persons will be required to file amendments if there are material changes to their percentage of ownership.

Key Dates

Keywords

Equillium, ADAR1 Capital, Schedule 13G, Beneficial Ownership, Biotechnology, Institutional Investor